PPADS tetrasodium is a non-selective P2X receptor antagonist used to inhibit recombinant P2X1, P2X2, P2X3, and P2X5 receptors (IC50: 1–2.6 μM), as well as native P2Y2-like (IC50 ~0.9 mM) and recombinant P2Y4 (IC50 ~15 mM) receptors; it acts as an inhibitor of the reverse mode of the Na⁺/Ca²⁺ exchanger (NCXrev) in guinea pig airway smooth muscle in a time- and concentration-dependent manner (1–30 μM, 10–50 minutes); it is effective at both native and recombinant P2X receptors, with highest sensitivity at human P2X1, P2X2, P2X3, P2X5, and P2X7 receptors (IC50 ~1–3 μM) and lower sensitivity at hP2X4R (IC50 ~30 μM); in vivo, it specifically and dose-dependently inhibits glomerular mesangial cell proliferation (without affecting non-mesangial cell proliferation) in a rat model of mesangial proliferative glomerulonephritis when administered intraperitoneally (15–60 mg/100 g body weight every 12 hours for 8 days).